JP2019526546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526546A5 JP2019526546A5 JP2019506649A JP2019506649A JP2019526546A5 JP 2019526546 A5 JP2019526546 A5 JP 2019526546A5 JP 2019506649 A JP2019506649 A JP 2019506649A JP 2019506649 A JP2019506649 A JP 2019506649A JP 2019526546 A5 JP2019526546 A5 JP 2019526546A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- heterocyclyl
- use according
- alkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- -1 substituted Chemical class 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 150000003053 piperidines Chemical class 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 208000033793 Neuroendocrine tumor of stomach Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical group NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000036506 well differentiated low or intermediate grade gastric neuroendocrine tumor Diseases 0.000 claims 1
- NBAIXBAUHIQQGF-UHFFFAOYSA-N CN1C(N(CC2)CCC2N)=NC(c(cc2F)ccc2C#N)=C(c(cc2)cc(F)c2OC)C1=O Chemical compound CN1C(N(CC2)CCC2N)=NC(c(cc2F)ccc2C#N)=C(c(cc2)cc(F)c2OC)C1=O NBAIXBAUHIQQGF-UHFFFAOYSA-N 0.000 description 2
- 0 *c(nc1)ccc1C(N=C(*)N1*)=C(*)C1=O Chemical compound *c(nc1)ccc1C(N=C(*)N1*)=C(*)C1=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662373263P | 2016-08-10 | 2016-08-10 | |
| US62/373,263 | 2016-08-10 | ||
| US201762468424P | 2017-03-08 | 2017-03-08 | |
| US62/468,424 | 2017-03-08 | ||
| PCT/US2017/046098 WO2018031658A1 (en) | 2016-08-10 | 2017-08-09 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526546A JP2019526546A (ja) | 2019-09-19 |
| JP2019526546A5 true JP2019526546A5 (enExample) | 2020-09-17 |
| JP6998938B2 JP6998938B2 (ja) | 2022-02-04 |
Family
ID=61162973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506649A Active JP6998938B2 (ja) | 2016-08-10 | 2017-08-09 | 再発性および／または難治性の固形腫瘍および非ホジキンリンパ腫の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10328077B2 (enExample) |
| EP (2) | EP3496721B1 (enExample) |
| JP (1) | JP6998938B2 (enExample) |
| KR (1) | KR102469406B1 (enExample) |
| CN (1) | CN109803660A (enExample) |
| AU (2) | AU2017310423B2 (enExample) |
| CA (1) | CA3033634A1 (enExample) |
| ES (1) | ES2972741T3 (enExample) |
| IL (2) | IL264718B2 (enExample) |
| MX (1) | MX381059B (enExample) |
| TW (1) | TWI767928B (enExample) |
| WO (1) | WO2018031658A1 (enExample) |
| ZA (1) | ZA201901322B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112368272B (zh) * | 2018-03-21 | 2023-04-21 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| EP3983016A4 (en) * | 2019-06-13 | 2023-06-07 | Celgene Corporation | CANCER TREATMENT METHODS BY TARGETING COLD TUMORS |
| CN116056707A (zh) * | 2020-06-05 | 2023-05-02 | 赛尔基因昆蒂赛尔研究公司 | 治疗前列腺癌的方法 |
| ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
| AU2023406476A1 (en) | 2022-12-02 | 2025-06-05 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| KR102670571B1 (ko) | 2023-09-25 | 2024-05-31 | 주식회사 디에스더블유 | 의류 건조기용 공기 가열장치 |
| CN119132626B (zh) * | 2024-05-29 | 2025-10-28 | 中山大学孙逸仙纪念医院 | 一种基于三级淋巴结构的新辅后三阴性乳腺癌预后预测方法及系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2710377A1 (en) * | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Therapeutic cancer treatments |
| WO2011050180A1 (en) * | 2009-10-21 | 2011-04-28 | Immunogen, Inc. | Novel dosing regimen and method of treatment |
| WO2012009475A1 (en) | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| WO2014085613A1 (en) * | 2012-11-30 | 2014-06-05 | Mccord Darlene E | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EA036672B8 (ru) | 2014-05-01 | 2021-01-13 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической деметилазы-1 |
-
2017
- 2017-08-09 CN CN201780062812.0A patent/CN109803660A/zh active Pending
- 2017-08-09 MX MX2019001608A patent/MX381059B/es unknown
- 2017-08-09 CA CA3033634A patent/CA3033634A1/en active Pending
- 2017-08-09 IL IL264718A patent/IL264718B2/en unknown
- 2017-08-09 EP EP17840210.3A patent/EP3496721B1/en active Active
- 2017-08-09 JP JP2019506649A patent/JP6998938B2/ja active Active
- 2017-08-09 ES ES17840210T patent/ES2972741T3/es active Active
- 2017-08-09 WO PCT/US2017/046098 patent/WO2018031658A1/en not_active Ceased
- 2017-08-09 IL IL303436A patent/IL303436A/en unknown
- 2017-08-09 EP EP23204042.8A patent/EP4286381A3/en not_active Withdrawn
- 2017-08-09 KR KR1020197006818A patent/KR102469406B1/ko active Active
- 2017-08-09 US US15/673,084 patent/US10328077B2/en active Active
- 2017-08-09 AU AU2017310423A patent/AU2017310423B2/en not_active Ceased
- 2017-08-10 TW TW106127044A patent/TWI767928B/zh not_active IP Right Cessation
-
2019
- 2019-03-01 ZA ZA2019/01322A patent/ZA201901322B/en unknown
- 2019-04-17 US US16/387,318 patent/US10548896B2/en active Active
- 2019-04-17 US US16/387,255 patent/US10543213B2/en active Active
- 2019-12-10 US US16/709,874 patent/US10849898B2/en active Active
-
2020
- 2020-06-10 US US16/898,044 patent/US10960005B2/en active Active
-
2022
- 2022-04-14 AU AU2022202495A patent/AU2022202495A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526546A5 (enExample) | ||
| JP2017519781A5 (enExample) | ||
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| JP2019526596A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2017514830A5 (enExample) | ||
| JP2005508923A5 (enExample) | ||
| JP2007524683A5 (enExample) | ||
| JP2020534263A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2011505347A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| JP2017505293A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| JP2005537323A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| JP2005527542A5 (enExample) | ||
| JP2017521364A5 (enExample) |